State Street saw its price target raised to $200 by Evercore ISI, reflecting an 8.7% potential upside, following strong Q2 financial results. The company reported earnings of $3.65 per share, beating estimates, and revenue grew 17% year-over-year to $4.05 billion. Positive economic conditions and a 10% dividend increase after passing the Fed's stress test support the optimistic outlook. Other analysts also upgraded their ratings, highlighting confidence in State Street's growth and valuation.
The global antiparasitic drugs market is projected to grow from $23.3 billion in 2026 to $30.98 billion by 2032, driven by persistent parasitic diseases, drug resistance, and climate change. Innovations focus on resistance-ready therapies, pediatric ...
The global activewear market is projected to grow from $439.74 billion in 2026 to $650.97 billion by 2032, at a CAGR of 6.59%. Growth is fueled by the rise of athleisure as everyday wear, increased health and fitness participation, and demand for ver...
JCDecaux has launched its programmatic digital Out-of-Home (pDOOH) advertising across nine Latin American countries, including Panama, Costa Rica, and Ecuador. This move allows brands to automate and optimize campaigns on over 4,600 digital screens, ...
JCDecaux has connected its entire Digital Out-of-Home (DOOH) inventory to programmatic buying across nine Latin American countries, including Panama, Costa Rica, and Ecuador. This move allows advertisers to plan and optimize campaigns more precisely ...
Immix Biopharma is under investigation by Block & Leviton for potential securities fraud after it was revealed that an executive using the name Richard Graydon was actually a fugitive operating under a false identity. The company fired the individual...
